Upcoming Dividend • May 25
Upcoming dividend of €0.20 per share Eligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Italian dividend payers (4.5%). Higher than average of industry peers (2.3%). Major Estimate Revision • May 13
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €151.3m to €145.0m. EPS estimate also fell from €1.46 per share to €1.27 per share. Net income forecast to grow 4.9% next year vs 33% growth forecast for Medical Equipment industry in Italy. Consensus price target down from €12.90 to €12.00. Share price fell 3.3% to €8.80 over the past week. Ankündigung • May 06
Svas Biosana S.p.A., Annual General Meeting, May 20, 2026 Svas Biosana S.p.A., Annual General Meeting, May 20, 2026, at 16:00 W. Europe Standard Time. Declared Dividend • Apr 19
Dividend reduced to €0.20 Dividend of €0.20 is 20% lower than last year. Ex-date: 1st June 2026 Payment date: 3rd June 2026 Dividend yield will be 2.2%, which is higher than the industry average of 1.7%. Sustainability & Growth The dividend has decreased by an average of 8.7% per year over the past 2 years, but has still been somewhat stable with no excessively large reductions to payments. EPS is expected to grow by 20% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • Apr 17
Svas Biosana S.p.A. announces Annual dividend, payable on June 03, 2026 Svas Biosana S.p.A. announced Annual dividend of EUR 0.2000 per share payable on June 03, 2026, ex-date on June 01, 2026 and record date on June 02, 2026. New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€45.7m market cap, or US$53.9m). New Risk • Jan 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (5.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€43.4m market cap, or US$50.5m). Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €8.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 15x in the Medical Equipment industry in Italy. Total loss to shareholders of 3.3% over the past three years. Ankündigung • Jun 26
Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million. Svas Biosana S.p.A. (BIT:SVS) signed a binding agreement to acquire 51% stake in Mehos S.R.L. for €0.9 million on June 26, 2025. The consideration of €0.9 million, to be paid over three years, in addition to an earn-out - a variable component linked to the achievement of specific economic results (EBITDA) in the next four years. SVAS has also committed to supporting the growth of MEHOS through a loan of 1 million, to be disbursed within three years. The transaction is expected to close by July 2025. The acquisition and the related financing commitment will be entirely supported by own funds.
For the period ending December 31, 2024, Mehos S.R.L. reported total revenue of €5.6 million and EBITDA of €7000. Upcoming Dividend • Jun 02
Upcoming dividend of €0.25 per share Eligible shareholders must have bought the stock before 09 June 2025. Payment date: 11 June 2025. Payout ratio is a comfortable 23% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Italian dividend payers (5.4%). Higher than average of industry peers (1.7%). Ankündigung • May 07
Svas Biosana S.p.A., Annual General Meeting, May 20, 2025 Svas Biosana S.p.A., Annual General Meeting, May 20, 2025, at 16:00 W. Europe Standard Time. Declared Dividend • Apr 20
Dividend reduced to €0.25 Dividend of €0.25 is 17% lower than last year. Ex-date: 9th June 2025 Payment date: 11th June 2025 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Ankündigung • Apr 19
Svas Biosana S.p.A. announces Annual dividend, payable on June 11, 2025 Svas Biosana S.p.A. announced Annual dividend of EUR 0.2500 per share payable on June 11, 2025, ex-date on June 09, 2025 and record date on June 10, 2025. New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€39.1m market cap, or US$44.3m). Price Target Changed • Jan 10
Price target decreased by 10% to €12.40 Down from €13.80, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €7.50. Stock is down 6.5% over the past year. Reported Earnings • Oct 01
First half 2024 earnings released First half 2024 results: Revenue: €59.0m (up 3.8% from 1H 2023). Net income: €2.62m (up 14% from 1H 2023). Profit margin: 4.4% (up from 4.0% in 1H 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in Italy. New Risk • May 09
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€43.5m market cap, or US$46.9m). Reported Earnings • May 02
Full year 2023 earnings released Full year 2023 results: Revenue: €121.6m (up 22% from FY 2022). Net income: €5.12m (up 44% from FY 2022). Profit margin: 4.2% (up from 3.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Italy. New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€44.0m market cap, or US$46.8m). Price Target Changed • Aug 07
Price target decreased by 16% to €13.80 Down from €16.40, the current price target is provided by 1 analyst. New target price is 64% above last closing price of €8.44. Stock is down 25% over the past year. The company is forecast to post earnings per share of €0.87 for next year compared to €0.66 last year. Reported Earnings • Apr 20
Full year 2022 earnings released Full year 2022 results: Revenue: €97.2m (up 19% from FY 2021). Net income: €3.57m (up 13% from FY 2021). Profit margin: 3.7% (down from 3.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Europe. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 03
First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021) First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €44.7m (up 129% from 1H 2021). Net income: €1.72m (up 74% from 1H 2021). Profit margin: 3.8% (down from 5.1% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Europe. Ankündigung • Jun 24
Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o. Svas Biosana S.p.A. (BIT:SVS) agreed to acquire 75% stake in the Bormia, trgovina in storitve, d.o.o. for EUR 4.8 million on May 17, 2022. With this transaction, Svas Biosana becomes a leader in the supply of medical devices in the Balkans area. The transaction involves the sale of a total of three shares in Bormia, representing 75% of the relative share capital, by the shareholders Maja Vecerina, Igor Bogatec and Boris Cotic, for a total consideration final amount of EUR 4.8 million, to be paid in full at closing.
Svas Biosana S.p.A. (BIT:SVS) completed the acquisition of a 75% stake in the Bormia, trgovina in storitve, d.o.o. on June 23, 2022. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Chairman of the Board of Directors Filippo Maraniello was the last director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Dec 11
SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million. SVAS Biosana S.p.A. has completed an IPO in the amount of €20 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,600,000
Price\Range: €12.5 
